HUMAN AMYLOID IMAGING CONFERENCE
January 17-19, 2018
The 12th Human Amyloid Imaging will take place in Miami, Florida on January 17-19, 2018. My co-organizers for the meeting will be, once more, Bill Klunk (University of Pittsburgh), Chet Mathis (University of Pittsburgh) and Bill Jagust (University of California, Berkeley).
At HAI 2018 we will continue to emphasize ample lively discussion of core controversies such as: what does the presence of brain amyloid mean, how should it be measured, how does it change, and what does it portend? Our discussions primarily sprung from brief presentations by active investigators who will report unpublished, cutting-edge research in human imaging of amyloid-beta and/or other biomarkers that pertain to Alzheimer’s-related disease.
To assemble HAI we will accept and peer-review only the most recent, important work, abstract submissions. The 2017 meeting drew more than 365 attendees and showcased 116 posters from research groups spanning North America, Europe, East Asia, and Australia.
Research reports are complemented at HAI by Keynote presentations that are intended to cross disciplines and provide perspective from neuropathology, neurochemistry, psychology, neurology, molecular imaging, clinical trials and biomarker research.
In 2018, we are pleased to welcome two such presentations from Drs. William Seeley (University of California, San Francisco) and Peter Davies (Northwell Health). In addition to these, we will continue our lectures on basic methods in amyloid PET.
Until our 12th edition of HAI, we invite you to bookmark our website, follow us on social media and save the dates in your calendars!
Keith A. Johnson, MD
Massachusetts General Hospital/Harvard Medical School
Save the conference dates to your calendars:
Keith Johnson, MD, Massachusetts General Hospital
William Jagust, MD, University of California, Berkeley
William Klunk, MD, University of Pittsburgh
Chester Mathis, PhD, University of Pittsburgh
HAI 2018 PROGRAM COMMITTEE
Thomas Beach, MD, PhD, Banner Health
Tammie Benzinger, MD, PhD, Washington University in St. Louis
Nenad Bogdanovic, PhD, University of Oslo
Gael Chetelat, PhD, INSERM/University of Caen Basse-Normandie
Brad Christian, PhD, University of Wisconsin
Teresa Gomez-Isla, MD, Massachusetts General Hospital
Roger Gunn, PhD, Imperial College
Kenji Ishii, MD, Tokyo Metropolitan Inst. of Gerontology
Milos Ikonomovic, MD, University of Pittsburgh
Clifford R. Jack, MD, Mayo Clinic
Robert A. Koeppe, PhD, University of Michigan
Mark Lubberink, PhD, Uppsala University
Beth Mormino, PhD, Stanford University
Melissa Murray, PhD, Mayo Clinic
Agneta Nordberg, PhD, Karolinska Institute
Rik Ossenkoeppele, PhD, VU University Medical Center Amsterdam
Denise Park, PhD, University of Texas
Julie Price, PhD, Harvard Medical School
Gil Rabinovici, MD, University of California, San Francisco
Susan Resnick, PhD, National Institute on Aging
Juha Rinne, MD, PhD, University of Turku
Sandra Sanabria, PhD, Genentech
Reisa Sperling, MD, Brigham and Women’s Hospital
Victor Villemagne, MD, The University of Melbourne
Sylvia Villeneuve, PhD, McGill University
2017 EVENT REVIEW
42 podium presentations were selected from 170 submitted abstracts featured over 2.5 days.
Thomas Beach, Marc Diamond, Howard Feldman, and Roger Gunn.
170 abstract submissions with 116 poster presentations in four 90-minute sessions.
9 podium presentation sessions were followed by 30 minute panel discussion and Q&A sessions.
Attendees will have the opportunity to review the basic, fundamental principles of amyloid and tau PET imaging, including radiochemistry and radio-tracer synthesis, PET acquisition and data processing, including application of corrections for the partial volume effect and co-registration with structural data. Particular attention will be given to the assessment of longitudinal PET data as it relates to methods of analysis and comparison to other domains of data, including structural and functional brain imaging data, and clinical and cognitive outcomes.
Data analysis procedures discussed will include voxel-based and region-based approaches, masking for vulnerable regions, and choice of statistical procedures and specific use of control groups from older age groups.
The concept of dichotomous versus continuous measures will continue to be extensively discussed, and the attendees should be able to characterize the advantages and disadvantages of both dichotomized and continuous variable approaches to analyses with respect to specific purposes or intended uses of the outcome.
Attendees will have the opportunity to evaluate and compare amyloid and tau PET data in specific clinical and clinical research contexts, including review of typical findings in Alzheimer’s disease dementia, mild cognitive impairment due to Alzheimer’s disease, and in clinically normal individuals. These phenomena will also be related to familial forms of the disease and to non-AD processes such as fronto-temporal lobar degeneration and dementia with Lewy Bodies, and chronic traumatic encephalopathy.
- Abstracts will be reviewed between November 7, 2017 and November 24, 2017.
- Podium/Poster Presenter notification of acceptance: on or around December 1, 2017.
- Travel scholarship notification: on or around December 4, 2017.
HOTEL ROOM BLOCK
- DISCOUNT ROOM BLOCK RATES will be available through December 11, 2017 or earlier (should block sell out).
COUNTDOWN TO 2018 CONFERENCE